INIS
stimulation
100%
evaluation
100%
economics
100%
spinal cord
100%
cost
90%
patients
63%
silicon carbides
54%
depreciation
18%
societal costs
18%
data
9%
values
9%
therapy
9%
comparative evaluations
9%
diabetes mellitus
9%
range
9%
probability
9%
investment
9%
pain
9%
limbs
9%
extrapolation
9%
Keyphrases
Best Medical Treatment
100%
Trial-based Economic Evaluation
100%
Painful Diabetic Neuropathy
100%
Spinal Cord Stimulation
100%
Quality-adjusted Life Years
36%
Cost-effectiveness
27%
Treatment Group
18%
Societal Costs
18%
Economic Evaluation
18%
Depreciation
18%
Incremental Cost-effectiveness Ratio
18%
Randomized Controlled Trial
9%
Diabetes Mellitus Complications
9%
Bootstrap
9%
Economic Burden
9%
Common Complications
9%
Carer Perspectives
9%
Conventional Therapy
9%
Willingness-to-pay Threshold
9%
Direct Medical Costs
9%
Bootstrap Analysis
9%
Initial Investment
9%
Lower Limb Pain
9%
Effective Range
9%
Societal Quality
9%
Humanistic Burden
9%
Nursing and Health Professions
Economic Evaluation
100%
Combination Therapy
100%
Spinal Cord Stimulation
100%
Diabetic Neuropathy
100%
Quality Adjusted Life Year
36%
Cost Effectiveness Analysis
27%
Incremental Cost-Effectiveness Ratio
18%
Treatment Group
18%
Diabetes Mellitus
9%
Health Care Cost
9%
Bootstrapping
9%
Limb Pain
9%
Health Care
9%
Medicine and Dentistry
Combination Therapy
100%
Diabetic Neuropathy
100%
Spinal Cord Stimulation
100%
Health Care Cost
63%
Cost-Effectiveness Analysis
45%
Quality Adjusted Life Year
36%
Treatment Group
18%
Randomized Controlled Trial
9%
Health Care
9%
Bootstrapping
9%
Complications of Diabetes Mellitus
9%
Lower Limb Pain
9%
Pharmacology, Toxicology and Pharmaceutical Science
Combination Therapy
100%
Diabetic Neuropathy
100%
Treatment Group
33%
Randomized Controlled Trial
16%
Diabetes Mellitus
16%
Limb Pain
16%
Biochemistry, Genetics and Molecular Biology
Spinal Cord Stimulation
100%
Painful Diabetic Peripheral Neuropathy
100%
Quality Adjusted Life Year
36%
Randomized Controlled Trial
9%
Immunology and Microbiology
Spinal Cord Stimulation
100%
Quality Adjusted Life Year
36%
Lower Limb
9%